PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
91.74%
Net income growth above 1.5x TRVN's 7.40%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-100.00%
Negative yoy D&A while TRVN is 868.19%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
100.00%
Well above TRVN's 2.53% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-95.76%
Both cut yoy SBC, with TRVN at -4.01%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-167.13%
Negative yoy working capital usage while TRVN is 104.52%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-230.77%
Negative yoy AP while TRVN is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-79.38%
Negative yoy usage while TRVN is 104.52%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-151.83%
Both negative yoy, with TRVN at -25.27%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
55.51%
Operating cash flow growth above 1.5x TRVN's 20.82%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
52.86%
Some CapEx rise while TRVN is negative at -103.68%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.86%
We have mild expansions while TRVN is negative at -103.68%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.